Recent Updates — BIOT
Instinct Bio Technical Company Holdings Inc. reported unaudited results for the six months ended May 31, 2026, showing revenue of USD 1,142,598, a 4.7% increase from the prior year period. The company returned to profitability with a profit after tax of USD 90,251, compared to a loss of USD 206,817 in the same period last year. Gross margin declined to 72.6% from 79.7%, primarily due to higher manufacturing overhead and new imported purchases. Administrative expenses fell 30.1% to USD 741,691 as listing-related professional fees did not recur. Net cash used in operating activities was USD 12,323, with cash balances decreasing to USD 25,565 from USD 124,764 at the end of the previous fiscal year. The company operates in the cosmetics and health products industry, developing and selling stem-cell-based and regenerative-medicine-related products.
Instinct Bio Technical Company Holdings Inc. received notifications from Nasdaq on September 9 and 10, 2026, indicating non-compliance with three continued listing requirements for the Nasdaq Global Market. The company failed to maintain a minimum market value of listed securities (MVLS) of $50 million, a minimum market value of publicly held shares (MVPHS) of $15 million, and a minimum bid price of $1.00 per share during periods ending in early September 2026. Nasdaq granted the company an 180-day compliance period until March 8 or 9, 2027, to regain compliance by meeting these thresholds for ten consecutive business days. Failure to comply may result in delisting proceedings, though the company may appeal or transfer to the Nasdaq Capital Market. The company is evaluating options to cure these deficiencies and has no guarantee of success. Instinct Bio Technical Company Holdings Inc. operates in the biotechnology industry, focusing on regenerative medicine, wellness technologies, and therapeutic platform development.
Instinct Bio Technical Company Holdings Inc. announced a cooperation agreement with PT Parva Candela on August 10, 2026, to jointly develop Indonesia’s cosmetics and personal care market. The partnership leverages PT Parva Candela's manufacturing facility and distribution network through its affiliated DELTASPA Group spa chain. Instinct Bio will provide proprietary formulations under the GENRÊVER and HAKUA brands, retaining intellectual property ownership while granting limited licenses. Revenue streams include a 50% profit share, ingredient supply fees, formulation royalties, and brand licensing. This initiative follows previous strategic announcements regarding an integrated clinic and a collaboration with Invitrx Therapeutics. Instinct Bio operates in the regenerative medicine, cosmetics, wellness, and consumer brands industry.
On July 30, 2026, Instinct Bio Technical Company Holdings Inc. announced a strategic collaboration with Invitrx Therapeutics, Inc., to expand its GENRÊVER cosmetic brand into the United States and explore regenerative medicine opportunities in Indonesia. The partnership leverages Instinct Bio's proprietary formulations and Invitrx's U.S. GMP manufacturing capabilities for product commercialization, while also evaluating the supply of concentrated exosomes and conditioned media for Indonesian clinics. This framework builds upon a six-year existing commercial relationship between the parties. As a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms, Instinct Bio aims to strengthen its international growth through these new market entries.
Instinct Bio announced an agreement with Dr. Mario Damianus Daniel Hadinoto to launch its Japanese aesthetic brand, GENRÊVER CLINIC, in Indonesia via a subscription-model membership beauty clinic business. The company plans an initial investment of approximately US$1 million to establish five directly operated clinics in major metropolitan areas including Jakarta, Surabaya, Bandung, Medan, and Bali. This initiative aims to create a recurring-revenue platform with transparent pricing and flexible cancellation terms, serving as a strategic gateway to the Company’s core regenerative medicine business involving stem-cell and iPS-cell technologies. Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms.